SCHEMBL12371513

SCHEMBL12371513

CCCCCCC[C@H](CC(=O)O)OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.58
MAPK1 P28482 4/20 0.47
MAPT P10636 4/20 0.47
GMNN O75496 3/20 0.47
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
CYP1A2 P05177 3/20 0.47
MEN1 O00255 2/20 0.47
HSP90AA1 P07900 2/20 0.47
BLM P54132 2/20 0.47
KMT2A Q03164 2/20 0.47
NR1H4 Q96RI1 2/20 0.47
TP53 P04637 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
HIF1A Q16665 1/20 0.47
FFAR1 O14842 2/20 0.47
FFAR4 Q5NUL3 1/20 0.47
GLA P06280 1/20 0.46
PMP22 Q01453 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28590845 1.00 GPR84 (0.58) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL20472006 1.00 GPR84 (0.58) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL23723113 1.00 GPR84 (0.58) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL20471823 1.00 GPR84 (0.58) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL28183600 0.98 GPR84 (0.55) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL2137297 0.92 GPR84 (0.47) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL3285285 0.86 GPR84 (0.60) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL3280835 0.86 GPR84 (0.60) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL21722645 0.85 GPR84 (0.47) GPR84MAPK1MAPTGMNNLMNA
SCHEMBL1679689 0.84 GPR84 (0.64) GPR84MAPK1MAPTGMNNLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994154-B2 Substituted liposaccharides useful in the treatment and prevention of endotoxemia Ersai R&D Management Co., Ltd. (JP) 2011-08-09 US disclosed
US-20100227835-A1 SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA EISAI R&D MANAGEMENT CO., LTD (JP) 2010-09-09 US disclosed
US-7737129-B2 Substituted liposaccharides useful in the treatment and prevention of endotoxemia EISAI R & D MANAGEMENT CO., LTD. (JP) 2010-06-15 US disclosed
US-20080214802-A1 Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia EISAI CO., LTD. (JP) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214802-A1 Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia LIPG, FUT6, UGCG GPR84 3138/4885MAPK1 3870/4885MAPT 4871/4885
US-20100227835-A1 SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA LIPG, FUT6, UGCG GPR84 3138/4885MAPK1 3870/4885MAPT 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.